AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7857355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study 2563388 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotinylated DNA probe
Number of subjects: 63
Study 805571 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (2000 to 2500 rads in two weeks)
Number of subjects: 700
Study 805571 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 700
Study 31126004 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical-sport education pilot programme (experimental group, n = 69)
Number of subjects: 113
Study 31126004 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 44)
Number of subjects: 113
Study 28992884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (400 mg/day)
Number of subjects: 86
Study 28992884 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2 g/day)
Number of subjects: 86
Study 26357467 — intervention group
Group type: EXPERIMENTAL
Intervention: LC350189 (10-600 mg single ascending dose)
Number of subjects: 125
Study 26357467 — intervention group
Group type: EXPERIMENTAL
Intervention: LC350189 (100-800 mg multiple ascending dose for 7 days)
Number of subjects: 125
Study 26357467 — intervention group
Group type: COMPARATOR
Intervention: LC350189 (200 mg)
Number of subjects: 125
Study 23851699 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified growing up milk (2.85 μg/100 ml)
Number of subjects: 92
Study 21516274 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD+β‐TCP
Number of subjects: 12
Study 21516274 — intervention group
Group type: COMPARATOR
Intervention: OFD
Number of subjects: 12
Study 19224790 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) remifentanil (1 ng/mL)
Number of subjects: 0
Study 19224790 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually controlled continuous infusion (MCI) remifentanil (0.125 microg x kg(‐1) x min(‐1) for 2 min followed by 0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 0
Study 19224790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline either as TCI or manual infusion of equivalent rate)
Number of subjects: 0
Study 16541851 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus rehabilitation training
Number of subjects: 46
Study 16541851 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training
Number of subjects: 46
Study 12928909 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pallidotomy
Number of subjects: 16
Study 12928909 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral STN-DBS
Number of subjects: 16
Study 12928909 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-operated matched PD patients)
Number of subjects: 16
Study 11079647 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PCI
Number of subjects: 323
Study 11079647 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab with reduced-dose reteplase (5 U double bolus)
Number of subjects: 323
Study 11079647 — intervention group
Group type: COMPARATOR
Intervention: No PCI
Number of subjects: 323
Study 9387746 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drugs (Tapazol and inderal, etc.)
Number of subjects: 69
Study 9387746 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine for tonifying Kidney and promoting blood circulation
Number of subjects: 69
Study 1549034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (50 mg)
Number of subjects: 12
Study 1549034 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 12
Study 1549034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3885813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg four times daily)
Number of subjects: 172
Study 3885813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 29127510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 31
Study 29127510 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Cryotherapy (WBC)
Number of subjects: 31
Study 29127510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 26866405 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage injection technique
Number of subjects: 100
Study 26866405 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 100
Study 24827078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar multisite pacing
Number of subjects: 17
Study 24827078 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar multisite pacing
Number of subjects: 17
Study 24827078 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular single-site pacing
Number of subjects: 17
Study 24827078 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar pacing
Number of subjects: 17
Study 21312072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus matrine
Number of subjects: 164
Study 21312072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 164
Study 21312072 — intervention group
Group type: COMPARATOR
Intervention: Control (no intraoperative PLC)
Number of subjects: 164
Study 21312072 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive PLC patients
Number of subjects: 164
Study 20383871 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment at a fixed dose of 50 IU/kg per week to increase hemoglobin level to a maximum of 13.7 g/dL for men and 13.4 g/dL for women.
Number of subjects: 75
Study 20383871 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment at a fixed dose of 50 IU/kg per week maintaining baseline hemoglobin levels for the first 6 months by phlebotomy.
Number of subjects: 75
Study 20383871 — intervention group
Group type: COMPARATOR
Intervention: Standard care without EPO (control group).
Number of subjects: 75
Study 18609249 — intervention group
Group type: EXPERIMENTAL
Intervention: General practices with older GPs
Number of subjects: 56978
Study 18609249 — intervention group
Group type: EXPERIMENTAL
Intervention: General practices in urban locations
Number of subjects: 56978
Study 18609249 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of practice assistant in diabetes care
Number of subjects: 56978
Study 18609249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperation with a diabetes nurse
Number of subjects: 56978
Study 18609249 — intervention group
Group type: EXPERIMENTAL
Intervention: General practices with younger GPs
Number of subjects: 56978
Study 18609249 — intervention group
Group type: EXPERIMENTAL
Intervention: General practices in urban settings
Number of subjects: 56978
Study 18609249 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate practice organization regarding diabetes care
Number of subjects: 56978
Study 18609249 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty of the GP in diabetes
Number of subjects: 56978
Study 16293867 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE-V regimen (Ifosfamide, carboplatin, etoposide, and vincristine)
Number of subjects: 402
Study 16293867 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (cyclophosphamide, doxorubicin, etoposide; cisplatin and etoposide)
Number of subjects: 402
Study 16293867 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE-V regimen
Number of subjects: 402
Study 16293867 — intervention group
Group type: COMPARATOR
Intervention: ICE-V regimen and Standard chemotherapy
Number of subjects: 402
Study 12564654 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (Foradil) 12 microg taken twice daily
Number of subjects: 500
Study 12564654 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (Foradil) 24 microg taken twice daily
Number of subjects: 500
Study 12564654 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (Foradil) used as regular maintenance treatment and rescue medication
Number of subjects: 500
Study 12564654 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (Foradil) total daily dose of 48 microg or less
Number of subjects: 500
Study 12564654 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (Foradil) regimen
Number of subjects: 500
Study 10214889 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride (AZ) 2 mg + S-carboxymethyl cysteine (SCMC) 750 mg
Number of subjects: 53
Study 10214889 — intervention group
Group type: COMPARATOR
Intervention: S-carboxymethyl cysteine (SCMC) 750 mg
Number of subjects: 53
Study 7611378 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day digoxin
Number of subjects: 12
Study 7611378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2171792 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 60
Study 2171792 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 60
Study 432544 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass (3:1 ratio)
Number of subjects: 24
Study 432544 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass (1:3 ratio)
Number of subjects: 24
Study 432544 — intervention group
Group type: COMPARATOR
Intervention: Unoperated
Number of subjects: 24
Study 31773810 — intervention group
Group type: EXPERIMENTAL
Intervention: Unassisted Netra
Number of subjects: 36
Study 31773810 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Netra
Number of subjects: 36
Study 31773810 — intervention group
Group type: COMPARATOR
Intervention: Professional subjective refraction
Number of subjects: 36
Study 30702997 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual pathway inhibition with low-dose rivaroxaban (2.5 mg twice-daily) plus acetylsalicylic acid
Number of subjects: 0
Study 30702997 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid alone
Number of subjects: 0
Study 29801012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration group (coached to drink more water)
Number of subjects: 631
Study 29801012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration group
Number of subjects: 631
Study 29801012 — intervention group
Group type: COMPARATOR
Intervention: Control group (coached to maintain usual intake)
Number of subjects: 631
Study 26717035 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced tacrolimus (EVR + Reduced TAC)
Number of subjects: 719
Study 26717035 — intervention group
Group type: COMPARATOR
Intervention: Conventional tacrolimus-based therapy (TAC Control)
Number of subjects: 719
Study 24374721 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma-reduction intervention involving training of 30 popular opinion leaders in each intervention hospital to disseminate stigma-reduction messages.
Number of subjects: 1760
Study 24374721 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma-reduction intervention
Number of subjects: 1760
Study 24374721 — intervention group
Group type: COMPARATOR
Intervention: Control condition (matched hospitals without the intervention)
Number of subjects: 1760
Study 21870979 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1 g twice a day)
Number of subjects: 0
Study 21870979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21870979 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study 20584997 — intervention group
Group type: EXPERIMENTAL
Intervention: Public insurance
Number of subjects: 776
Study 20584997 — intervention group
Group type: COMPARATOR
Intervention: Uninsured
Number of subjects: 776
Study 20584997 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all insurance statuses)
Number of subjects: 776
Study 20584997 — intervention group
Group type: COMPARATOR
Intervention: Insurance status
Number of subjects: 776
Study 17554878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/Acetaminophen
Number of subjects: 40
Study 17554878 — intervention group
Group type: COMPARATOR
Intervention: Calcium gluconate
Number of subjects: 40
Study 16254224 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz, 25 minutes)
Number of subjects: 0
Study 16254224 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 11903066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cardiopulmonary bypass with alpha-stat
Number of subjects: 60
Study 11903066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cardiopulmonary bypass with pH-stat
Number of subjects: 60
Study 11903066 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardiopulmonary bypass with alpha-stat
Number of subjects: 60
Study 11903066 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardiopulmonary bypass with pH-stat
Number of subjects: 60
Study 11903066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cardiopulmonary bypass
Number of subjects: 60
Study 11903066 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardiopulmonary bypass
Number of subjects: 60
Study 10065662 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg patch for 22 weeks (L-25)
Number of subjects: 3575
Study 10065662 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg patch for 8 weeks (S-25)
Number of subjects: 3575
Study 10065662 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg patch for 22 weeks (L-15)
Number of subjects: 3575
Study 10065662 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg patch for 8 weeks (S-15)
Number of subjects: 3575
Study 10065662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P-0)
Number of subjects: 3575
Study 7488408 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative platinum-based chemotherapy (two cycles)
Number of subjects: 174
Study 7488408 — intervention group
Group type: COMPARATOR
Intervention: RPLND alone
Number of subjects: 174
Study 7488408 — intervention group
Group type: COMPARATOR
Intervention: Pathological stage A
Number of subjects: 174
Study 1962154 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound treatment (1 MHz; 1:4; 1 W/cm2, 10 min/session, 2-3 times weekly for 10 treatments)
Number of subjects: 45
Study 1962154 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 45
Study 6127896 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol 12.5, 25, and 50 micrograms
Number of subjects: 18
Study 6127896 — intervention group
Group type: COMPARATOR
Intervention: Prenalterol after hydralazine and isosorbide dinitrate
Number of subjects: 18
Study 6127896 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 18
Study 31629646 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Discharge Team (SDT)
Number of subjects: 403
Study 31629646 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 403
Study 31092165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885
Study 31092165 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885
Study 29117413 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted clear corneal incision (LENSAR, Inc., Orlando, FL)
Number of subjects: 62
Study 29117413 — intervention group
Group type: COMPARATOR
Intervention: Manual clear corneal incision (with a 2.4-mm keratome)
Number of subjects: 62
Study 26071040 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA 1 g
Number of subjects: 4000
Study 26071040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study 23873583 — intervention group
Group type: EXPERIMENTAL
Intervention: Double therapy (peginterferon α‐2b and ribavirin for 20 weeks)
Number of subjects: 233
Study 23873583 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (peginterferon α‐2b, ribavirin, and boceprevir for 24 weeks)
Number of subjects: 233
Study 22313979 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno IV
Number of subjects: 90
Study 22313979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond
Number of subjects: 90
Study 22313979 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt‐L‐Pop
Number of subjects: 90
Study 22313979 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE One
Number of subjects: 90
Study 22313979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bond Force
Number of subjects: 90
Study 22313979 — intervention group
Group type: COMPARATOR
Intervention: Optibond
Number of subjects: 90
Study 20571786 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide treatment (20 microg/day)
Number of subjects: 44
Study 17643390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 52
Study 17643390 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 52
Study 15651569 — intervention group
Group type: EXPERIMENTAL
Intervention: New procedure for measuring fluorescein leakage using confocal scanning laser ophthalmoscope (CSLO)
Number of subjects: 0
Study 15651569 — intervention group
Group type: COMPARATOR
Intervention: Existing methods for assessment of fluorescein leakage (qualitative evaluation of fluorescein angiographies and volume measurements by Fluorotron Master)
Number of subjects: 0
Study 12383454 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier first intercourse
Number of subjects: 79
Study 12383454 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 79
Study 10024114 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH (12 IU/day)
Number of subjects: 24
Study 10024114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7594255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dayroom program focused on functional needs
Number of subjects: 0
Study 2261895 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy based formula
Number of subjects: 21
Study 2261895 — intervention group
Group type: COMPARATOR
Intervention: Full cream cows' milk or low lactose formula
Number of subjects: 21
Study 6805002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (10-70 mg/day, median 30 mg/day)
Number of subjects: 40
Study 6805002 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (600-1500 mg/day, median 900 mg/day)
Number of subjects: 40
Study 6805002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 40
Study 6805002 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 40
Study 6805002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide and Chlorpromazine
Number of subjects: 40
Study 31350391 — intervention group
Group type: EXPERIMENTAL
Intervention: FluBlok
Number of subjects: 0
Study 31350391 — intervention group
Group type: COMPARATOR
Intervention: FluCelvax
Number of subjects: 0
Study 31350391 — intervention group
Group type: COMPARATOR
Intervention: Fluzone
Number of subjects: 0
Study 31350391 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat vaccinations (all platforms)
Number of subjects: 0
Study 31350391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior year vaccination
Number of subjects: 0
Study 28727908 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8666 500 mg
Number of subjects: 63
Study 28727908 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8666 150 mg
Number of subjects: 63
Study 28727908 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8666 50 mg
Number of subjects: 63
Study 28727908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 26348088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SRT) treatment, maximum dose 200 mg/day, over 72-300 days (mean=164.2, SD=68.3).
Number of subjects: 11
Study 23566419 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg) twice daily for two to three weeks (n = 22)
Number of subjects: 37
Study 23566419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 37
Study 23566419 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib vs Placebo
Number of subjects: 37
Study 22060250 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Modification Paradigm (AMP)
Number of subjects: 17
Study 22060250 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 17
Study 19549430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone 400 micrograms once daily for 12 weeks
Number of subjects: 26
Study 19549430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17720853 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hop bract polyphenols (HBP) mouthrinse
Number of subjects: 29
Study 17720853 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 29
Study 16702870 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% carboxymethylcellulose (CMC)
Number of subjects: 0
Study 16702870 — intervention group
Group type: COMPARATOR
Intervention: propylene glycol/polyethylene glycol 400 (PG‐HPG)
Number of subjects: 0
Study 15143476 — intervention group
Group type: EXPERIMENTAL
Intervention: 11PncTD1 (1 dose of adjuvanted, 11-valent pneumococcal conjugate vaccine)
Number of subjects: 0
Study 15143476 — intervention group
Group type: COMPARATOR
Intervention: 11PncTD3 (3 doses of adjuvanted, 11-valent pneumococcal conjugate vaccine)
Number of subjects: 0
Study 15143476 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 11PncTD1 and 11PncTD3
Number of subjects: 0
Study 10748306 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 26
Study 10748306 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 26
Study 10748306 — intervention group
Group type: COMPARATOR
Intervention: Brachial artery diameter
Number of subjects: 26
Study 10748306 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial artery diameter change
Number of subjects: 26
Study 8729585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg
Number of subjects: 0
Study 8729585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 0
Study 8729585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg and 40 mg
Number of subjects: 0
Study 8729585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 0
Study 1568660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA, 12 mg/kg/day)
Number of subjects: 48